1 results match your criteria 0598 placebo

  • Page 1 of 1

Changes in insulin sensitivity and insulin secretion with the sodium glucose cotransporter 2 inhibitor dapagliflozin.

Diabetes Technol Ther 2014 Mar 15;16(3):137-44. Epub 2013 Nov 15.

1 Center for Metabolic Research, VA San Diego Healthcare System, and University of California , San Diego, San Diego, California.

Aim: This randomized, double-blind, placebo-controlled parallel-group study assessed the effects of sodium glucose cotransporter 2 inhibition by dapagliflozin on insulin sensitivity and secretion in subjects with type 2 diabetes mellitus (T2DM), who had inadequate glycemic control with metformin (with or without an insulin secretagogue).

Subjects And Methods: Forty-four subjects were randomized to receive dapagliflozin 5 mg or matching placebo once daily for 12 weeks. Subjects continued stable doses of background antidiabetes medication throughout the study. Read More

View Article and Full-Text PDF
  • Page 1 of 1